Neoadjuvant chemotherapy in geriatric head and neck cancers
- 1 March 2017
- journal article
- research article
- Published by Wiley in Head & Neck
- Vol. 39 (5) , 886-892
Abstract
Background: The purpose of this study was to present our findings on the treatment completion rates and outcomes in geriatric patients with head and neck cancer treated with neoadjuvant chemotherapy followed by definitive therapy.Methods: Geriatric patients with locally advanced head and neck cancer who received neoadjuvant chemotherapy were selected for this analysis. Overall survival (OS) and progression‐free survival (PFS) were estimated.Results: Forty‐six of 49 patients completed neoadjuvant chemotherapy (93.9%). The compliance to local treatment was 73.3% and the median OS was 49.9 months (95% confidence interval [CI] = 22.0–77.8 months) in patients who received neoadjuvant chemotherapy for organ preservation (n = 15). In patients receiving neoadjuvant chemotherapy for technically unresectable disease, the corresponding figures were 82.06% and 9.0 months (95% CI = 5.9–12.1 months), respectively.Conclusion: Individualized neoadjuvant chemotherapy protocols in geriatric patients have high compliance rates to treatment and the median OS in geriatric patients treated for organ preservation is similar to that of young patients. © 2017 Wiley Periodicals, Inc. Head Neck 39: 886–892, 2017Keywords
This publication has 27 references indexed in Scilit:
- Elective versus Therapeutic Neck Dissection in Node-Negative Oral CancerNew England Journal of Medicine, 2015
- A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neckOral Oncology, 2015
- Referral pattern for neoadjuvant chemotherapy in the head and neck cancers in a tertiary care centerIndian Journal of Cancer, 2014
- Treatment of Older Patients With Head and Neck Cancer: A ReviewThe Oncologist, 2013
- Comorbidity in head and neck cancer: A critical appraisal and recommendations for practiceOral Oncology, 2010
- Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck CancerNew England Journal of Medicine, 2007
- Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck CancerNew England Journal of Medicine, 2007
- Trends in incidence and prognosis for head and neck cancer in the United States: A site‐specific analysis of the SEER databaseInternational Journal of Cancer, 2005
- Reasons for non-standard treatment in elderly patients with advanced head and neck cancerEuropean Archives of Oto-Rhino-Laryngology, 2004
- Impact of comorbidity on the outcome of laryngeal squamous cancerHead & Neck, 2003